Overview
Sightera Biosciences revolutionizes drug discovery through AI-powered analysis of patient-derived models for breakthrough therapeutics in cancer and regenerative medicine.
Key people
In the news
- At the HealthTech Investor Summit (HIS) 2026, we’ll close with a powerful alumni panel: 🎤 𝗪𝗵𝗮𝘁 𝗛𝗮𝗽𝗽𝗲𝗻𝘀 𝗔𝗳𝘁𝗲𝗿 𝘁𝗵𝗲 𝗣𝗶𝘁𝗰𝗵? 𝗠𝗲𝗲𝘁 𝗛𝗜𝗦 𝗔𝗹𝘂𝗺𝗻𝗶 𝗪𝗵𝗼 𝗠𝗮𝗱𝗲 𝗜𝘁 𝗛𝗮𝗽𝗽𝗲𝗻 A pitch may only last 7 minutes, but the real journey starts afterwards. Investor meetings, due diligence, strategic partnerships, fundraising rounds and growth plans all play a role in transforming promising health innovations into successful companies. That is why we’re bringing together three former HIS participants who
- Last week, Maria Fonseca joined #BostonBiotechWeek and #RESI in Boston on behalf of Obulytix, connecting with investors, biotech entrepreneurs, researchers, and industry leaders from across the life sciences ecosystem. A particular highlight was sharing the experience with the Belgian biotech delegation and exchanging perspectives on the challenges and opportunities of translating innovation from bench to patient in our local ecosystem. At RESI, organized by Life Science Nation, we gained valuable insights into US and
- We are heading to Boston! 🇺🇸 From September 21–24, Sightera Biosciences will be attending #RESIBOSTON and LSX Congress USA taking part in the Belgian Mission to Boston, alongside VIB, Biovia, Flanders Investment & Trade - USA and SLL Alumni network, bringing Belgian biotech innovation to one of the world's leading life sciences hubs. Our CEO Hendrik Vercammen and CBO Lars Vanlommel will be on the ground, meeting with pharma partners, investors, and fellow innovators to share where our platform and pipeline in oncology and fibrosis
- Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platformSightera Biosciences, a Belgiantechbio company using generative AI to develop novel small-molecule therapies,has raised €3 million in a pre-seed funding round led by Entourage, Anacura andQBIC.A spin-...
Tech.eu · 17 Jul 2026
- 𝐒𝐢𝐠𝐡𝐭𝐞𝐫𝐚 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐢𝐬 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐨𝐮𝐫 𝐩𝐫𝐞-𝐬𝐞𝐞𝐝 𝐫𝐨𝐮𝐧𝐝 𝐨𝐟 €𝟑 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 ✨ We raised €3M in pre-seed funding, backed by Entourage Ventures, Anacura & Qbic Fund | Venture Capital, combining deep expertise in both AI and biotech, around the same table. Sightera is a techbio company that uses artificial intelligence to discover and design new medicines, with a current focus on oncology and fibrosis. But we do things differently from most: our AI learns
- BIO2026 in San Diego is a wrap, and what a convention it has been! 🇺🇲 Meeting after meeting, the same question kept coming up: how do you actually get from patient-derived data to an innovative drug candidate faster? That's the conversation we love having. Our platform is built on proprietary patient-derived data, and we walked partners through how that translates directly into our own therapeutic pipeline in oncology and fibrosis. Given the current market landscape and strong industry traction around novel payload classes,
- Sightera Biosciences is heading to BIO International Convention in San Diego! Our co-founders will be representing Sightera at one of the biggest gatherings in biotech, bringing together innovators, investors, and pharma partners from across the globe. We'll be there to connect with founders, investors, and pharma partners who share our conviction that the next breakthroughs in drug discovery will come from combining AI with high-quality, clinically relevant patient data. If you're heading to San Diego June 22–25, let's connect,
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.